Reirradiation and hyperthermia for radiation-associated sarcoma

Authors

  • Marianne A. A. de Jong MD,

    1. Department of Radiation Oncology and Hyperthermia, Academic Medical Center, Amsterdam, the Netherlands
    Search for more papers by this author
  • Sabine Oldenborg MD,

    1. Department of Radiation Oncology and Hyperthermia, Academic Medical Center, Amsterdam, the Netherlands
    Search for more papers by this author
  • S. Bing Oei MD,

    1. Department of Radiation Oncology and Hyperthermia, Verbeeten Institute, Tilburg, the Netherlands
    Search for more papers by this author
  • Vanessa Griesdoorn MD,

    1. Department of Radiation Oncology and Hyperthermia, Academic Medical Center, Amsterdam, the Netherlands
    2. Department of Radiation Oncology and Hyperthermia, Verbeeten Institute, Tilburg, the Netherlands
    Search for more papers by this author
  • M. Willemijn Kolff MD,

    1. Department of Radiation Oncology and Hyperthermia, Academic Medical Center, Amsterdam, the Netherlands
    Search for more papers by this author
  • Caro C. E. Koning MD, PhD,

    1. Department of Radiation Oncology and Hyperthermia, Academic Medical Center, Amsterdam, the Netherlands
    Search for more papers by this author
  • Geertjan van Tienhoven MD, PhD

    Corresponding author
    1. Department of Radiation Oncology and Hyperthermia, Academic Medical Center, Amsterdam, the Netherlands
    • Academic Medical Centre, Department of Radiation Oncology and Hyperthermia, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands

    Search for more papers by this author
    • Fax: (011) 31-20-6091278


  • We are grateful to Paul Zum Vörde sive Vörding and Jacques Venselaar, without whom hyperthermia at our departments would not be possible, and to Otto Visser from the Comprehensive Cancer Center Amsterdam for providing the Netherlands Cancer Registry data.

Abstract

BACKGROUND:

The objective of this study was to evaluate the role of reirradiation and hyperthermia in the treatment of radiation-associated sarcoma (RAS) in the thoracic region, which is an increasing, yet extremely rare condition with a poor prognosis.

METHODS:

Between 1979 and 2009, 16 patients with RAS in the thoracic region were treated in the Academic Medical Center and the Institute Verbeeten with reirradiation and hyperthermia. In 13 patients, this treatment was given for unresectable disease and 3 times after resection as adjuvant treatment. The median latency period between the original malignancy diagnosis and the RAS diagnosis was 86 months (range 19-212 months). Histology was angiosarcoma in 11 patients (69%). The literature on reirradiation with or without hyperthermia for RAS was reviewed.

RESULTS:

The median survival was 15.5 months (range, 3-204 months). Four patients were not evaluable for response. The response rate for the remaining 12 patients was 75% (7 complete responses and 2 partial responses). Six patients remained free of local failure until death (5 months and 7 months) or last follow-up (8 months, 11 months, 39 months, and 68 months).

CONCLUSIONS:

The current study indicates that combined reirradiation and hyperthermia for RAS in the thoracic region is feasible. The high response rate and the possibility of durable local control suggest that this treatment is promising. Cancer 2012;. © 2011 American Cancer Society.

Ancillary